Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 2/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | POLG | P54098 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.49 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065119 | 1.00 | TGM2 (0.62) | TGM2POLBFUT5P2RY6P2RY2 | |
| SCHEMBL25712474 | 1.00 | TGM2 (0.62) | TGM2POLBFUT5P2RY6P2RY2 | |
| Deoxy Adenosinediphosphate SCHEMBL5827743 | 0.99 | TGM2 (0.63) | TGM2POLBFUT5P2RY6P2RY2 | |
| Deoxy Adenosinediphosphate SCHEMBL5827749 | 0.99 | TGM2 (0.63) | TGM2POLBFUT5P2RY6P2RY2 | |
| SCHEMBL20442307 | 0.92 | POLB (0.61) | TGM2POLBFUT5P2RY6P2RY2 | |
| SCHEMBL2922052 | 0.92 | POLB (0.61) | TGM2POLBFUT5P2RY6P2RY2 | |
| SCHEMBL5334255 | 0.91 | FUT5 (0.58) | TGM2POLBFUT5P2RY6P2RY2 | |
| SCHEMBL23584319 | 0.90 | FUT5 (0.64) | TGM2POLBFUT5P2RY6P2RY2 | |
| SCHEMBL4380341 | 0.90 | TGM2 (0.51) | TGM2POLBFUT5P2RY6P2RY2 | |
| SCHEMBL15833359 | 0.90 | FUT5 (0.64) | TGM2POLBFUT5P2RY6P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390479-A1 | TAIL-CONJUGATED RNAS | TIBA BIOTECH (US) | 2024-11-28 | — | — | US | claimed |
| WO-2023212213-A1 | TAIL-CONJUGATED RNAS | TIBA BIOTECH (US) | 2023-11-02 | — | — | WO | claimed |
| US-9115380-B2 | Kits and methods for generating 5′ capped RNA | CELLSCRIPT, LLC (US) | 2015-08-25 | — | — | US | claimed |
| US-20150191760-A1 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | CELLSCRIPT LLC (US) | 2015-07-09 | — | — | US | claimed |
| US-9005930-B2 | Kits and methods for generating 5′ capped RNA | CELLSCRIPT, LLC (US) | 2015-04-14 | — | — | US | claimed |
| US-20140363876-A1 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | EPICENTRE TECHNOLOGIES | 2014-12-11 | — | — | US | claimed |
| US-8846348-B2 | Kits and methods for generating 5′ capped RNA | CELLSCRIPT, LLC (US) | 2014-09-30 | — | — | US | claimed |
| US-20140221248-A1 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | CELLSCRIPT, LLC (US) | 2014-08-07 | — | — | US | claimed |
| EP-2010659-B1 | Kits and methods for generating 5' capped RNA | CELLSCRIPT INC (US) | 2014-06-18 | — | — | EP | claimed |
| EP-2010659-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | Epicentre Technologies (US) | 2009-01-07 | — | — | EP | claimed |
| US-20070281336-A1 | Kits and methods for generating 5' capped RNA | EPICENTRE TECHNOLOGIES (US) | 2007-12-06 | — | — | US | claimed |
| WO-2007120863-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | EPICENTRE TECHNOLOGIES (US) | 2007-10-25 | — | — | WO | claimed |
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | ISMAILI HICHAM MOULAY ALAOUI (CA) | 2004-12-09 | — | — | US | claimed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | claimed |
| US-20260117290-A1 | METHOD FOR AMPLIFYING COMPLEMENTARY DNA STRAND | IMMUNOGENETEQS, INC. (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4721752-A2 | HERSTELLUNG UND VERWENDUNG VON IN VITRO-SYNTHETISIERTER SSRNA ZUR EINFÜHRUNG IN SÄUGETIERZELLEN ZUR INDUKTION EINER BIOLOGISCHEN ODER BIOCHEMISCHEN WIRKUNG | CELLSCRIPT, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260028621-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2026-01-29 | — | — | US | disclosed |
| WO-2007120863-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | EPICENTRE TECHNOLOGIES (US) | 2007-10-25 | — | — | WO | disclosed |
| US-6482938-B1 | Compounds having energy transfer function and method for DNA base sequencing by using the same | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| EP-0967219-A1 | COMPOUNDS HAVING ENERGY TRANSFER FUNCTION AND METHOD FOR DNA BASE SEQUENCING BY USING THE SAME | THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH (JP) | 1999-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | TGM2 2757/4885POLB 693/4885FUT5 156/4885 |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | TGM2 2757/4885POLB 693/4885FUT5 156/4885 |
| US-20260028621-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | NSUN2, RNMT, RNGTT | TGM2 3888/4885POLB 95/4885FUT5 3019/4885 |
| US-20260117290-A1 | METHOD FOR AMPLIFYING COMPLEMENTARY DNA STRAND | RNGTT, POLRMT, POLM | TGM2 2159/4885POLB 6/4885FUT5 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.